RxDoctor Payments Data

Julia Magdici

Family · Peoria, AZNPI 1720569924

Payments from drug & device makers

$2,189in general payments, 2019–2025

Across 127 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$606
  • Novo Nordisk$474
  • Amgen$242
  • Corcept Therapeutics$121
  • Novartis$98
  • Radius Health, Inc.$96
  • plus $551 from 11 others

What the payments were for

  • Food & beverage$2,16399%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,189 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$15,371
Medicare patients
72
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$194,954
MounjaroTirzepatide125$136,554
Tresiba Flextouch U-200Insulin Degludec17$37,779
TrulicityDulaglutide33$37,321
Tresiba Flextouch U-100Insulin Degludec54$29,780
RybelsusSemaglutide18$25,668
JardianceEmpagliflozin20$23,577
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/720$17,859
FarxigaDapagliflozin Propanediol15$15,537
JanuviaSitagliptin Phosphate17$15,147
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$11,512
GlyxambiEmpagliflozin/Linagliptin12$7,148
Gvoke Hypopen 2-PackGlucagon12$6,847
Insulin Lispro Kwikpen U-100Insulin Lispro19$4,904
Humalog Kwikpen U-100Insulin Lispro14$4,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$474$222,919191 claims
Lilly USA, LLCMounjaro, Trulicity$72$173,875158 claims
Boehringer IngelheimJardiance, Glyxambi$59$30,72432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →